MedTrace Logo

Efficacy, Safety, and Pharmacokinetics of LP-003 Injection in Allergic Asthma Patients

NCT07342803 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2026-01-15

No results posted yet for this study

Summary

This is a multicenter, randomized, masked, active and placebo controlled, Phase II clinical study to evaluate the efficacy, safety, and pharmacokinetics of LP-003 injection in adult patients with moderate to severe persistent allergic asthma.

Conditions

  • Allergic Asthma

Interventions

BIOLOGICAL

LP-003 Injection

s.c. injection, Q12W

BIOLOGICAL

Omalizumab

s.c. injection, Q4W

BIOLOGICAL

Placebo

s.c. injection, Q4W

Sponsors & Collaborators

  • Longbio Pharma

    lead INDUSTRY

Principal Investigators

  • Jieming Qu · Ruijin Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-25
Primary Completion
2027-12-28
Completion
2029-09-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07342803 on ClinicalTrials.gov